# Study to Evaluate Arikace™ in CF Patients With Chronic Infection Due to Pseudomonas Aeruginosa

> **NCT01315691** · PHASE3 · WITHDRAWN · sponsor: **Insmed Incorporated**

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** Liposomal amikacin for inhalation
- **DRUG:** Placebo for liposomal amikacin for inhalation

## Key facts

- **NCT ID:** NCT01315691
- **Lead sponsor:** Insmed Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2018-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01315691

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01315691, "Study to Evaluate Arikace™ in CF Patients With Chronic Infection Due to Pseudomonas Aeruginosa". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01315691. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*